FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 250 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR ESMO Clinical Practice Guideline Express Update on the adoption of physical... January 27, 2026 Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... June 6, 2019 Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 Load more HOT NEWS An Important Part of Cancer Caregiving That’s Often Overlooked and How... Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ Receiving a Blood Transfusion During Cancer: What to Know and What...
